Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06962956

Evaluating Gingivitis and Systemic Biomarkers

This exploratory study will consist of two parts: Phase 1 (sample collection/screening) and Phase 2 (sample collection/product efficacy testing). The purpose of Phase 1 is to understand the association of gingivitis to systemic biomarkers and to screen subjects for Phase 2. The purpose of Phase 2 is to assess the causal effect of oral hygiene intervention on gingivitis and systemic biomarkers.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

25 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Salus Research

Fort Wayne, Indiana, 46825, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provide informed consent and receive a signed copy of the informed consent form;
  • Be between 25 - 65 years of age;
  • Have at least 16 gradable teeth;
  • Have a minimum of (approximately) 30% of bleeding sites and no more than two teeth with pockets deeper than 5mm or deemed acceptable by the Investigator/Designee (unhealthy test subjects only);
  • Have less than or equal to 3 bleeding sites and with all pockets less than or equal to 3mm deep (healthy test subjects only);
  • Agree to fast 12 hours prior to any visit with a blood collection;
  • Agree to not perform any oral hygiene for at least 12 hours prior to any visit with dental exams, saliva collection, and plaque collections;
  • Agree to refrain from eating or drinking, using medicated lozenges, breaths mints, and chewing gum at least 4 hours prior to this study visit (exception allowed: small sips of water up until 45 minutes prior to their appointment) for any visit with plaque collections;
  • Agree to refrain from use of any non-study oral hygiene products after the Product Distribution visit;
  • Agree to continue their current oral hygiene products and habits until the Product Distribution visit;
  • Agree to delay any elective dentistry, including dental prophylaxis outside of the study protocol, until the completion of the study;
  • Agree to all study restrictions for the duration of the study (medicines/supplements/vaccines- see restricted list);
  • Agree not to participate in any other oral care studies for the duration of this study;
  • Agree to return for all scheduled visits and to follow all study procedures; and
  • Be in good general health, as determined by the Investigator/Designee based on a review of their health history.

Exclusion criteria

  • Severe periodontal disease, including but not limited to purulent exudate, generalized mobility, and/or severe recession;
  • Active treatment for gingivitis, periodontitis, or caries;
  • Daily use of NSAID;
  • Having any of the following: fixed orthodontic appliances or attachments for aligner treatment, lower bonded retainers; removable partial dentures, peri/oral piercings, a pacemaker or other implanted device, unless deemed acceptable by the Investigator/Designee;
  • A condition requiring the need for antibiotic premedication prior to dental procedures;
  • Use of anti-inflammatory or anti-coagulant medications within 2 weeks of the Baseline visit, unless deemed acceptable by the Investigator/Designee;
  • Having had oral/gum surgery within the previous 2 months;
  • Smoking or vaping (regardless of content), use of smokeless tobacco, e-cigarettes, or nicotine patches);
  • Currently using recreational drugs;
  • Having been diagnosed with cardiovascular disease, diabetes (having an A1C ≥ 7), rheumatoid arthritis, liver disease, IBS, Crohn's Disease, Chronic Kidney Disease, or any type of autoimmune disease;
  • Having any gastrointestinal issues (e.g. diarrhea, vomiting) in the past week;
  • Use of statins or cholesterol lowering medication or supplements (e.g., Flax seeds, omega-3 fatty acids, Magnesium Oxide ≥250mg, Zyflamed, supplements containing berberine, golden thread, turmeric, CoQ10, or quercetin) for the duration of the study;
  • Use of antibiotics or having a dental prophylaxis in the last 4 weeks prior the baseline visit, unless deemed acceptable by the Investigator/Designee;
  • Receiving a flu shot or other vaccination in the last 4 weeks prior the baseline visit;
  • Inability to undergo any study procedures;
  • Currently undergoing treatment with GLP-1s antagonist;
  • Nursing, self-reported pregnancy or the intention of becoming pregnant any time during the course of this study; or
  • Having any condition or disease, as determined by the Investigator/Designee based on a review of the medical history which could be expected to interfere with examination procedures or with the subject's safe completion of the study.

Treatment and study plan

0.76% Sodium Monofluorophosphate Dentifrice

Drug

Brush two times a day for 1 minute with manual toothbrush

0.454% Stannous Fluoride Dentifrice

Drug

Brush two times a day for 1 minute with manual toothbrush

Primary outcomes

  1. Number Bleeding Sites

    Time frame: 4 months

    Total number of bleeding sites

Sponsors and collaborators

Lead sponsor

Procter and Gamble

Industry

Registry information

Official study title

An Exploratory Study to Evaluate the Relationship Between Gingivitis and Systemic Biomarkers

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
May 8, 2025
Registry last updated
Jun 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.